The second edition of SPECTAforum met its objectives with representation of most of the stakeholders. With SPECTAcolor, the first platform, now rapidly reaching over 200 patients, SPECTA, an innovative approach to efficient access to molecular target-based clinical trials, has demonstrated international feasibility. Routes for stakeholders to join SPECTA are now being launched. Additional disease-oriented platforms are actively being developed and will be launched soon.
SPECTAforum 2014: Videos available for viewing
Methodologies for conducting trials and other studies, including data handling and analysis at ESTRO-EORTC wor... 26/04/2017
27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) – EORTC session: Infections... 06/04/2017